-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, AE9MDOeo2kOsk8oNwviAjM63ZOv9u7C8fNOXAILYAefSso0q2PO4llq17E7FEtpJ pXXF6u9BCpmwIqmFdMVYZw== 0001193125-07-057689.txt : 20070319 0001193125-07-057689.hdr.sgml : 20070319 20070319083117 ACCESSION NUMBER: 0001193125-07-057689 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20070316 ITEM INFORMATION: Other Events FILED AS OF DATE: 20070319 DATE AS OF CHANGE: 20070319 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PDL BIOPHARMA, INC. CENTRAL INDEX KEY: 0000882104 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943023969 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19756 FILM NUMBER: 07701924 BUSINESS ADDRESS: STREET 1: 34801 CAMPUS DR CITY: FREMONT STATE: CA ZIP: 94555 BUSINESS PHONE: 5105741400 MAIL ADDRESS: STREET 1: 34801 CAMPUS DR CITY: FREMONT STATE: CA ZIP: 94555 FORMER COMPANY: FORMER CONFORMED NAME: PROTEIN DESIGN LABS INC/DE DATE OF NAME CHANGE: 19930328 8-K 1 d8k.htm FORM 8-K Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (date of earliest event reported):

March 16, 2007

 

PDL BioPharma, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware   000-19756   94-3023969
(State or other jurisdiction
of incorporation)		   (Commission File No.)   (I.R.S. Employer
Identification No.)

34801 Campus Drive

Fremont, California 94555

(Address of principal executive offices)

Registrant’s telephone number, including area code:

(510) 574-1400

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Item 8.01. Other Events.

On March 16, 2007, after approval of Alexion Pharmaceuticals, Inc.’s (“Alexion”) Soliris™ (eculizumab) humanized antibody product by the U.S. Food and Drug Administration, in order to protect PDL BioPharma, Inc.’s (the “Company”) intellectual property rights, the Company filed a lawsuit against Alexion seeking monetary damages for infringement of certain of the Company’s patents. Because the Company does not seek to deprive patients with paroxysmal nocturnal hemoglobinuria and physicians from access to Alexion’s Soliris™ (eculizumab) humanized antibody product, the Company is not seeking an injunction against Alexion. The Company has not yet served its complaint on Alexion.

The Company has contacted Alexion about a license to Alexion under certain of the Company’s antibody humanization patents, commonly referred to as the Queen patents, and is seeking to meet with Alexion to discuss negotiation of license terms.

 

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 19, 2007

 

PDL BioPharma, Inc.

By:

  

/s/ Andrew Guggenhime

  Andrew Guggenhime
 

Senior Vice President and Chief Financial Officer

 

3

-----END PRIVACY-ENHANCED MESSAGE-----